Breaking News

ten23 Unveils Major Expansion in Switzerland on swissfillon Site

Will expand into a fully-dedicated building in Visp-West with two additional sterile manufacturing lines.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

ten23 health, a global contract development and manufacturing organization (CDMO), announced an additional expansion of swissfillon’s manufacturing site in Visp, canton of Valais, Switzerland, which was acquired October 2021. The FDA- and Swissmedic-inspected site in Visp currently offers sterile manufacturing of pre-filled syringes, vials and cartridges for clinical trial and market supplies. The recent news concerns the setup of a new manufacturing building in Visp-West, fully dedicated to ten...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters